HC Wainwright & Co. Downgrades RAPT Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

February 21, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RAPT Therapeutics was downgraded from Buy to Neutral by HC Wainwright & Co. analyst Raghuram Selvaraju.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they may reflect a less optimistic outlook on the company's future performance. Given the downgrade is from Buy to Neutral, it suggests a significant shift in the analyst's view, potentially leading to decreased investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100